Report topline Phase 1b EQUATE data in itolizumab aGVHD study
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 9 Mar 2021
- Due
- 30 Jun 2021
- Delivered
- June 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Topline Phase 1b data expected 1H 2021, informs further development strategy in aGHVD, cGVHD, and GVHD prevention”
What we found
Evidence strength A What the grades mean
Later 10-Q filings state that topline Phase 1b EQUATE results were announced in June 2021, before the 30 June 2021 deadline.
-
A Equillium, Inc. 10-Q filed 2021-08-10
“In June 2021, we announced positive topline results from the Phase 1b portion of the EQUATE study.” ✓ confirmed on the page
-
A Equillium, Inc. 10-Q filed 2021-11-10
“In June 2021, we announced positive topline results from the Phase 1b portion of the EQUATE study.” ✓ confirmed on the page
Checked 27 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
- Deliverable
- Topline Phase 1b EQUATE trial data for itolizumab
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Equillium, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-EQ-025445 · Corrections policy